CJC-1295 (No DAC) / IpamorelinUnderstand the science
What a single-compound time course can show about a proposed pairing
2 numbered sourcesSource years 1999, 2024
Peptides consist of short amino-acid chains connected by peptide bonds. The time a signaling peptide remains in blood can differ from the time the body responds to it. CJC-1295 (No DAC) / Ipamorelin names a modified growth hormone–releasing hormone fragment and ipamorelin, a five-residue ghrelin-receptor agonist. Would the timing of ipamorelin's effect by itself predict the timing of the two-peptide response? [1, 2]
An older study in healthy male volunteers measured both ipamorelin and growth hormone (GH) in blood. Investigators estimated a terminal half-life of about two hours for ipamorelin in that protocol. The GH curve showed a single episode of release, with a peak less than an hour after the study exposure began and a decline afterward. The study used a mathematical model to describe how the compound concentration related to the delayed hormone response. [2]
The two curves answer different questions. The drug curve tracks the presence of ipamorelin, while the hormone curve follows the pituitary's response. The hormone concentration can change for reasons that include the body's release pattern and its clearance of GH. Separating the two curves helps scientists interpret a time course without assuming the signal remains active for exactly as long as the compound remains measurable. [2]
No recent primary study tracing both compounds and growth hormone after exposure to the exact catalog pair was identified. The 1999 human findings concern ipamorelin alone. Establishing the combined time course would require direct measurement of the specified no-DAC analogue and the downstream hormone response, along with appropriate comparison conditions. The amount of time the two peptides remain present together would be an additional measurement in its own right. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
